Antimuscarinic Bronchodilator Response Retained after Bronchoscopic Vagal Denervation in Chronic Obstructive Pulmonary Disease Patients
Koegelenberg, Coenraad Frederik N.; Theron, Johan; Slebos, Dirk-Jan; Klooster, Karin; Mayse, Martin; Gosens, Reinoud

Published in:
Respiration

DOI:
10.1159/000447641

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Acetylcholine from parasympathetic nerves remains a well-validated target to treat patients with chronic obstructive pulmonary disease (COPD). Current treatment guidelines recommend anticholinergics as first-line therapy for mild to advanced COPD [1]. Targeted lung denervation (TLD) is a novel bronchoscopic therapy that ablates the parasympathetic innervation of the lungs and has a similar proposed mechanism of action to anticholinergic drugs [2]. In the first-in-man non-randomized, uncontrolled, prospective, sequential, two-dose study (NCT01483534), we found TLD to be feasible, safe, and well tolerated [2]. In the original study, TLD was performed on COPD patients ≥40 years of age with a ratio of the forced expiratory volume in 1s (FEV₁) to the forced vital capacity of ≤0.70 and a postbronchodilator FEV₁ of 30–60% of predicted normal values [2]. Patients had to have a smoking history of ≥10 pack-years and no history of asthma [2]. Only patients with a 15% or greater relative increase in FEV₁ following inhalation of 80 μg ipratropium bromide were included in this study [2]. Patients underwent staged TLD at 20 or 15 W following baseline assessment off bronchodilators [2]. Assessments were repeated off bronchodilators (including antimuscarinics) at 30, 90, 180, 270, and 365 days after TLD.

Twelve patients (FEV₁ 33.8 ± 9.4% predicted) were treated at a 20-watt energy dose and 10 patients (FEV₁ 34.5 ± 6.3% predicted) at 15 W. The clinical safety profiles were similar between the two energy doses. The results for the 20-watt cohort suggest larger and more durable improvements in lung function (FEV₁ +11.6%), exercise capacity (submaximal cycle endurance +6.8 min), and health-related quality of life (St. George’s Respiratory Questionnaire −11.9) [2]. We subsequently aimed to investigate whether the antimuscarinic bronchodilator response was retained in patients with COPD who underwent TLD in the pilot study.

A post hoc analysis was performed to specifically assess the peak bronchodilator response (increase in FEV₁) following inhalation of 80 μg ipratropium, which was performed as part of the study at 90, 180, and 365 days. The bronchodilator response was measured at 30 and 60 min following the administration of ipratropium, and the peak was defined as the higher of the two values.

Categorical data were tabulated with counts and percentages. All available data were summarized, with no imputation for missing data. An independent statistical group (NAMSA, Minneapolis, Minn., USA) conducted the final analyses using SAS V.9.3 (SAS Institute, Cary, N.C., USA).

All 22 patients were included in the post hoc analysis. Six months’ follow-up data were complete for all patients. One-year follow-up data were available in 11 of 12 patients in the 20-watt cohort and in 9 of 11 patients in the 15-watt cohort.

The bronchodilator response achieved by 80 μg ipratropium at peak at 90, 180, and 365 days after TLD is summarized in table 1 and figure 1. Postbronchodilator FEV₁ was significantly different from prebronchodilator FEV₁ at all time points (p < 0.05), implying that the bronchodilator response achieved by inhaled ipratropium at peak was not blunted in patients who underwent TLD. The greatest bronchodilator response was observed in patients treated with 20 W, with a mean response of 355 ml (42.8%) at 1-year follow-up.

Our findings suggest that simultaneous targeting of acetylcholine release and function by TLD and antimuscarinics provides additive bronchodilatory effects. Partial reinervation of bisected effenter parasympathetic motor nerves is known to occur as is unstimulated low-grade constant release of acetylcholine at the postganglionic membranes, and both these effects may explain the interactive effects [3].

Our data also suggest that vagal denervation at the level of the main bronchi is unlikely to result in complete and permanent suppression of the distal parasympathetic nervous system in the airways. The impressive bronchodilation achieved by inhaled ipratropium in patients who underwent TLD strongly favours this postulation and also suggests that future research should focus on the combination of TLD and inhaled long-acting muscarinic antagonist.

An alternative explanation lies in the potential anti-inflammatory effects of TLD [4]. Our understanding of the parasympathetic innervation of the lungs as well as the role of acetylcholine release in health and diseased states has evolved over the last 2 decades. Acetylcholine production in the airways is now known not to be restricted to the parasympathetic nervous system. It is also released from non-neuronal sources such as the bronchial epithelium and inflammatory cells [5]. Evidence suggests that acetylcholine may play an integral role in regulating the mechanisms that drive the chronic airway inflammation in COPD [3–5]. Many other factors above and beyond the vagal nerve therefore influence the

© 2016 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/res
We excluded patients with a history of recurrent respiratory infections from the original study and allowed the use of inhaled corticosteroids during baseline testing and follow-up, which may be viewed as limitations when interpreting the post hoc analysis.

In conclusion, the bronchodilator response achieved by inhaled ipratropium was retained in patients who underwent TLD.

Table 1. The bronchodilator response achieved by 80 μg ipratropium at peak at 90, 180, and 365 days after TLD

<table>
<thead>
<tr>
<th>Change in FEV&lt;sub&gt;1&lt;/sub&gt; from baseline</th>
<th>Pre-TLD</th>
<th>90 days</th>
<th>180 days</th>
<th>365 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 W TLD alone, prebronchodilator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Litre</td>
<td>0.085±0.073</td>
<td>0.098±0.070</td>
<td>0.049±0.088</td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>12.5±7.8</td>
<td>13.5±7.2</td>
<td>11.6±10.2</td>
<td></td>
</tr>
<tr>
<td>Postbronchodilator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Litre</td>
<td>0.265±0.043</td>
<td>0.316±0.058</td>
<td>0.259±0.089</td>
<td>0.355±0.074</td>
</tr>
<tr>
<td>%</td>
<td>28.2±2.5</td>
<td>36.7±4.9</td>
<td>29.6±7.5</td>
<td>42.8±6.5</td>
</tr>
<tr>
<td>15 W TLD alone, prebronchodilator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Litre</td>
<td>0.030±0.039</td>
<td>0.079±0.052</td>
<td>−0.001±0.043</td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>2.9±4.7</td>
<td>9.6±5.8</td>
<td>0.0±4.8</td>
<td></td>
</tr>
<tr>
<td>Postbronchodilator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Litre</td>
<td>0.166±0.011</td>
<td>0.232±0.042</td>
<td>0.210±0.031</td>
<td>0.123±0.045</td>
</tr>
<tr>
<td>%</td>
<td>19.8±0.6</td>
<td>27.9±5.8</td>
<td>24.5±4.0</td>
<td>15.0±4.8</td>
</tr>
</tbody>
</table>

Data are shown as mean ± standard error of the mean.
Acknowledgments
We acknowledge the work of the late Chris T. Bolliger, MD, PhD, for his important contributions in the collection of the data and Kristina T. Rouw, PhD, for her role in the data analysis.

Financial Disclosure and Conflicts of Interest
All clinical trial expenses were reimbursed by the study sponsor (Holaira, Inc., Minneapolis, Minn., USA). M.M. is an employee of the study sponsor. D.-J.S. reports grants, personal fees, and non-financial support from Holaira Inc. during the conduct of the study.

References